ATM and cancer: Healthy subjects carrying germline variants in BRCA1, BRCA2, PALB2, CDKN2A, ATM, and MMR genes can be referred to as dedicated intensive surveillance programs, which may include risk-reducing measures for several cancer types (breast, ovarian, prostate cancers, colorectal cancer, and melanoma) as standard of care or in research settings to reduce morbidity and mortality due to those syndromes [49].